Hepatitis C virus kinetics and optimized therapy in DAA treatment

2016 Fiscal Year Final Research Report

• Project/Area Number: 15K19586
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Infectious disease medicine
• Research Institution: Kyushu University
• Principal Investigator: Eiichi Ogawa 九州大学, 医学研究院, 助教 (70621283)
• Research Collaborator: NORIHIRO Furusyo 九州大学, 大学院・医学研究院 感染制御医学分野, 准教授 (10346786) ; MASAYUKI Murata 九州大学, 病院・総合診療科, 講師
• Project Period (FY): 2015-04-01 – 2017-03-31
• Keywords: C型肝炎ウイルス / リアルタイムPCR法 / DAA

Outline of Final Research Achievements

The study was carried out to compare the ability of two HCV RNA assays (TaqMan and AccuGene assays) to evaluate the impact of hepatitis C virus (HCV) kinetics on the outcome of patients treated with triple therapy or interferon-free sofosbuvir-based therapy.
In triple therapy, the time HCV RNA became undetectable by the AccuGene assay was associated with treatment outcome for difficult-to-treat group, such as patients with advanced fibrosis, IL28B TG/GG genotype (rs8099917), and prior non-responders. In sofosbuvir-based therapy, the time at which HCV RNA became target not detected was not associated with treatment outcome by either the AccuGene or TaqMan assay.

Free Research Field

感染症学